First-line immunotherapy in advanced non-squamous non-small cell lung cancer patients with rare mutations: a retrospective cohort study.

Transl Lung Cancer Res · 2025 · PMC12337050 · PMID 40799440

Europe PMC DOI

hedged sentence

0.4600

closest p · 9.2× alpha

0.4600

boldest claim

The sentences

a favorable trendP=0.46not close (p > 0.1)

Additionally, there was a favorable trend in the ORR (35.90% vs. 29.63%, P=0.46) and median PFS (14.53 vs. 7.03 months, P=0.10) ( Table S3 and Figure 3 ).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.